
About Hemanext
Hemanext is a Healthcare company based in Lexington (United States) founded in 2004 by Martin Cannon. Technologies for blood and product storage are developed. Hemanext has raised $127.57 million across 10 funding rounds from investors including HHS. The company has 53 employees. Its chief executive, as recorded, is Andrew Dunham. Hemanext offers products and services including Hemanext ONE. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Instruments and Preservation. Its legal entity is Hemanext, Inc. Its competitors include Brooks Automation, Bridge to Life and Cold Chain Technologies; 1 of its 3 listed competitors has raised funding.
Company details
Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.
- Headquarters Lexington, United States
- Employees 53
- Founders Martin Cannon
- SectorsHealthcare
- Phoneโขโขโขโข โขโขโขโข
- Website hemanext.com
- Social LinkedIn X Facebook Instagram
- Legal Name Hemanext, Inc.
- Total Equity Funding$127.57M (USD)
in 10 rounds
- Latest Funding Round$18.9M (USD), Series B
Jul 2025
- Investors
- Employee Count53
Products & Services of Hemanext
Hemanext offers a comprehensive portfolio of products and services, including Hemanext ONE.
Processes red blood cells to mitigate storage lesions and improve quality.
Funding Insights of Hemanext
Hemanext has successfully raised a total of $127.57M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $18.9 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $127.57M
- Total Rounds 10
- Last Round Series B โ $18.9M
- First Round $1.89M
(Mar 2009)
- Investors Count 1
All 10 funding rounds of Hemanext with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $18.9M | Series B | โ | โ | โ |
| Jan 2025 | $20M | Series B | โ | โ | โ |
| Nov 2024 | $21.71M | Series B | โ | โ | โ |
| Dec 2023 | $5.01M | Series B | โ | โ | โ |
| Jun 2023 | $11.29M | Series B | โ | โ | โ |
| Nov 2022 | $18M | Series B | โ | โ | โ |
| Oct 2020 | $21.22M | Series B | โ | โ | โ |
| Oct 2018 | $8.75M | Series A | โ | โ | โ |
| Dec 2017 | $2.7M | Seed | โ | โ | โ |
| Mar 2009 | $1.89M | Grant | โ | โ |
1 investors in total: 1 institutional.
Investors in Hemanext
Hemanext has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Public health and human services are overseen by HHS. | 1953 | hhs.gov |
Investor details for Hemanext
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Hemanext
25 people are tracked at Hemanext (14 in leadership, 8 in board & advisors, 3 in team); the tracked headcount is 53.
| Name | Role | Group |
|---|---|---|
Martin Cannon | Founder | Leadership |
Andrew Dunham | CEO & CTO | Leadership |
Jill Buckley | VP, Human Resources | Leadership |
Daan Kok | EVP & General Manager, EMEA | Leadership |
Laura Daniels | VP, Product Development | Leadership |
Mike McNamara | Chief Markets Officer, Investor, And Advisor To The Board Of Directors | Leadership |
Phyllis Haines Bergeron | Director, Field Implementation Program Manager | Leadership |
Robert Haime | VP, Commercial Operations | Leadership |
Eric Newman | CFO | Leadership |
Alex Marichal | Vice President Global Commercial Development | Leadership |
James N. Hourani | Associate Director Of Medical Information | Leadership |
Laurel Omert | Chief Medical Officer | Leadership |
Michael McGraw | Associate Director, Product Development | Leadership |
Suzanna van Straaten | Sr. Director Commercial And Market Access EMEA | Leadership |
Steve Eckert | Board Member | Board & advisors |
David Testa | Board Member | Board & advisors |
Richard Perle | Board Member | Board & advisors |
William O'Neill | Board Member | Board & advisors |
Eduardo Avayú | Board Member | Board & advisors |
Guy Cogan | Board Member | Board & advisors |
5 more people are available in the full profile.
Complete people profiles for Hemanext
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Hemanext
3 dated milestones of Hemanext across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Hemanext is founded.
- Funding First funding round of $1.9M.
- Funding Latest funding round, Series B, of $18.9M.
Competitors of Hemanext
Hemanext has 3 listed competitors in our database, 1 of them funded. They include Brooks Automation, Bridge to Life and Cold Chain Technologies.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| brooks.com | 1978 | Chelmsford, United States | 1,928 | Vacuum robots for semiconductor wafer handling are developed. | ||
| bridgetolife.com | 2012 | Columbia, United States | $57M | Cold storage solutions for organ transplant preservation are provided. | ||
| coldchaintech.com | 2001 | Franklin, United States | Thermal packaging solutions and cold chain monitoring services are provided. |
Detailed competitors of Hemanext
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Hemanext
The website of Hemanext (hemanext.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 55.4% vs previous month
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Hemanext (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track โ from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hemanext
Complete news archive for Hemanext
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hemanext
Hemanext was founded in 2004 and raised its 1st funding round 5 years after it was founded.
Hemanext is headquartered in Lexington, United States. It is registered at Lexington, Kentucky, United States.
Andrew Dunham is the CEO of Hemanext, as recorded in our data.
Hemanext is a funded company, having raised a total of $127.57M across 10 funding rounds to date. The company's 1st funding round was a Grant of $1.89M, raised on Mar 2009.
Hemanext has 53 employees.
Founded in 2004 and based in Lexington, United States, operations are focused on biotechnology for blood preservation. Two key technologies have been developed: Hemanext, which enables red blood cell storage under anaerobic conditions, and the MicroVascular Analyzer, used to measure red blood cell deformability. Applications include addressing hypercoagulability, inflammation, impaired perfusion, and immuno-modulation in therapeutic settings.
Hemanext's top competitors include Brooks Automation, Bridge to Life and Cold Chain Technologies.
Hemanext offers Hemanext ONE.
Hemanext has 1 investor. Key investors include HHS.
Hemanext operates through Hemanext, Inc..
